NCT01959386View on ClinicalTrials.gov

A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer

CompletedOBSERVATIONAL

Enrollment

1,006

Participants

Timeline

Start Date

November 7, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Breast Neoplasms

Interventions

DRUG

Trastuzumab

Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.

Trial Locations (1)

55131

Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01959386 - A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer | Biotech Hunter | Biotech Hunter